Abstract

BackgroundNontuberculous mycobacterial (NTM) infection in immunocompromized patients is currently a growing health concern, and we aimed to examine the relative risk of NTM infection in patients with Sjögren’s syndrome (SS) compared with that in non-SS individuals.MethodsWe used the 2003–2012 Taiwanese National Health Insurance Research Database to identify 6554 incident SS cases during 2007–2012 and selected 98,310 non-SS controls matched (1:15) for age, gender, and the year of first SS diagnosis date after excluding those who had rheumatoid arthritis or systemic lupus erythematosus.ResultsWe identified four NTM-infected patients in the SS group (three in the first year) and nine in the non-SS group (three in the first year). SS patients had a higher incidence rate of NTM infection than that in non-SS individuals (IRR, 7.56; 95% CI, 2.33–24.55), especially during the first year (IRR, 16.05; 95% CI, 3.24–79.51). After adjusting for potential confounders, the risk of NTM infection was not increased in SS patients during the entire follow-up period or during the first year, but the risk increased in SS patients treated with immunosuppressants during the entire follow-up period (HR, 17.77; 95% CI, 4.53–69.61), especially during the first year (HR, 33.33; 95% CI, 4.37–254.23).ConclusionAn increased risk of NTM infection was found in SS patients treated with immunosuppressants during the first year after SS diagnosis.

Highlights

  • Nontuberculous mycobacterial (NTM) infection in immunocompromized patients is currently a growing health concern, and we aimed to examine the relative risk of NTM infection in patients with Sjögren’s syndrome (SS) compared with that in non-SS individuals

  • We found that SS patients had a higher Charlson comorbidity index (CCI) (0.5 ± 0.9 vs. 0.4 ± 1.0, P < 0.001) and were more likely to receive corticosteroids (69.6% vs. 39.0%, P < 0.001), cyclophosphamide (3.2% vs. 0.4%, P < 0.001), methotrexate (8.6% vs. 0.4%, P < 0.001), and azathioprine (12.5% vs. 0.1%, P < 0.001) (Table 1)

  • Comparison of the incidence of NTM infection among SS patients with that among non-SS individuals Table 2 shows a comparison of the incidence rate of NTM infection among SS patients with that among non-SS individuals

Read more

Summary

Introduction

Nontuberculous mycobacterial (NTM) infection in immunocompromized patients is currently a growing health concern, and we aimed to examine the relative risk of NTM infection in patients with Sjögren’s syndrome (SS) compared with that in non-SS individuals. Sjögren’s syndrome (SS), affecting approximately 1% of the general population, is a systemic chronic inflammatory disorder characterized by lymphocytic infiltrates in the exocrine glands and is primarily manifested with an insidious onset of dry eyes and dry mouth [1, 2]. Management of SS primarily consists of symptomatic treatment of sicca complaints and corticosteroids, while immunosuppressive agents, including azathioprine, Chao et al BMC Infectious Diseases (2017) 17:796 with incident SS using a nationwide, population-based cohort

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call